Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-c3 in Recurrent or Persistent Uterine Serous Carcinoma
CTR20220321Phase 2Terminated
- Sponsor
- Not applicable
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azenosertib in Serous endometrial adenocarcinoma, sponsored by Not applicable. Started Feb 2022; status: terminated.
02
Drugs
azenosertib
03
Conditions
Serous endometrial adenocarcinoma
Beyond the preview
Go deeper on CTR20220321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220321.